Dashboard
Manage Tickers

REGNREGENERON PHARMACEUTICALS, ...

Nasdaq regeneron.com


$ 987.53 $ 4.98 (0.51 %)    

Monday, 20-May-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ 3.15 (0.7 %)
DIA $ 398.57 $ -1.85 (-0.46 %)
SPY $ 530.36 $ 0.61 (0.12 %)
TLT $ 91.26 $ -0.27 (-0.3 %)
GLD $ 225.37 $ 0.90 (0.4 %)
$ 987.27
$ 979.99
$ 0.00 x 0
$ 0.00 x 0
$ 978.33 - $ 987.56
$ 684.81 - $ 998.33
310,879
na
113.63B
$ 0.53
$ 29.46
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-05-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-06-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-07-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-08-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-07-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-07-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 02-08-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-09-2017 12-31-2016 10-K
31 11-04-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-11-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-04-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-12-2015 12-31-2014 10-K
39 11-04-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

regn---analyzing-regeneron-pharmaceuticalss-short-interest
(REGN) - Analyzing Regeneron Pharmaceutica...
05/20/2024 19:15:23

Core News & Articles
Regeneron Pharmaceuticals And Sanofi Prese...
05/20/2024 18:17:57

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% ...

insights-into-regeneron-pharmaceuticalss-performance-versus-peers-in-biotechnology-sector
Insights Into Regeneron Pharmaceuticals's ...
05/17/2024 15:00:51

heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-10-years
Here's How Much You Would Have Made Owning...
05/14/2024 14:30:25

evercore-isi-group-initiates-coverage-on-regeneron-pharmaceuticals-with-outperform-rating-announces-price-target-of-1150
Evercore ISI Group Initiates Coverage On R...
05/14/2024 09:13:39

Evercore ISI Group analyst Cory Kasimov initiates coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform rati...

Core News & Articles
Regeneron Pharmaceuticals And Sanof's Dupi...
05/13/2024 07:00:51

If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately c...

regeneron-announces-prelim-data-in-an-asgct-presentation-showing-db-oto-improved-hearing-to-normal-levels-in-one-child-within-24-weeks-initial-hearing-improvements-observed-in-a-second-child-at-6-week-assessment
Regeneron Announces Prelim. Data In An ASG...
05/08/2024 10:03:41

assessing-regeneron-pharmaceuticals-insights-from-16-financial-analysts
Assessing Regeneron Pharmaceuticals: Insig...
05/03/2024 16:00:21

cantor-fitzgerald-reiterates-neutral-on-regeneron-pharmaceuticals-maintains-925-price-target
Cantor Fitzgerald Reiterates Neutral on Re...
05/03/2024 15:27:50

Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and maintains $925...

regeneron-pharmaceuticals-targets-quality-weight-loss-in-latest-obesity-innovation
Regeneron Pharmaceuticals Targets Quality ...
05/02/2024 19:49:45

Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatm...

wall-street-inches-up-after-powells-inflation-remarks-chipmakers-rebound-gold-crude-falter-whats-driving-markets-thursday
Wall Street Inches Up After Powell's Infla...
05/02/2024 17:37:33

U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.

industry-comparison-evaluating-regeneron-pharmaceuticals-against-competitors-in-biotechnology-industry
Industry Comparison: Evaluating Regeneron ...
05/02/2024 15:00:43

heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-20-years
Here's How Much You Would Have Made Owning...
05/02/2024 14:30:22

regeneron-pharmaceuticals-q1-2024-adj-eps-955-misses-1010-estimate-sales-3145b-miss-3221b-estimate
Regeneron Pharmaceuticals Q1 2024 Adj EPS ...
05/02/2024 10:31:29

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $9.55 per share which missed the analyst consensus estim...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
04/30/2024 17:35:25

behind-the-scenes-of-regeneron-pharmaceuticalss-latest-options-trends
Behind the Scenes of Regeneron Pharmaceuti...
04/30/2024 14:31:36

regeneron-presents-eye-treatment-results-with-eylea-hd-at-vision-research-meeting
Regeneron Presents Eye Treatment Results w...
04/29/2024 11:02:39

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the presentation of positive long-term results and subgroup analy...

abbvies-dermatitis-drug-shown-superior-to-sanofiregenerons-dupixent-in-head-to-head-study
AbbVie's Dermatitis Drug Shown 'Superior' ...
04/25/2024 17:58:29

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficac...

regeneron-mammoth-partner-to-pursue-next-generation-crispr-based-gene-editing-for-multiple-diseases-mammoth-to-receive-100m-total-upfront-payment-and-equity-investment
Regeneron, Mammoth Partner To Pursue Next-...
04/25/2024 11:28:00

Under the terms of the agreement, Mammoth will receive $100 million inclusive of $95 million in equity investment at signing, a...

td-cowen-maintains-buy-on-regeneron-pharmaceuticals-raises-price-target-to-1030
TD Cowen Maintains Buy on Regeneron Pharma...
04/24/2024 17:39:04

TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target fr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION